FORM 4

obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ALEXANDER SUSAN H</u>						2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]								neck all appl Direct	icable)		erson(s) to Issuer 10% Owner Other (specify	
(Last) (First) (Middle) BIOGEN IDEC INC. 225 BINNEY STREET					3. Date of Earliest Transaction (Month/Day/Year) 02/23/2014								A below	below) below) EVP, Chief Legal Officer				
(Street) CAMBRIDGE MA 02142				_ 4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)								dividual or Joint/Group Filing (Check Applicable c) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S		(Zip)	Di-	4.							-						
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				action	2/ E: ur) if	A. Deemed xecution Date, any Month/Day/Year)		3. Transa Code (3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		5. Amo Securit Benefic	unt of ies ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	ction(s)			msu. 4)	
Common Stock 02/23/2					3/2014	.014		M		3,821	. A	\$0	23,930			D		
Common Stock 02/23/2					3/2014	.014		F		1,803	D	\$347.	11 22	2,127	1	D		
		Т	able II -									, or Ben ble secu		/ Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,		Transaction Code (Instr.		n of E		6. Date Exercisa Expiration Date (Month/Day/Yea		7. Title an Amount o Securities Underlyin Derivative (Instr. 3 an	f g Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactio (Instr. 4)	S F	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Restricted Stock Unit	\$0 ⁽¹⁾	02/23/2014			M			3,821	(2)	(02/23/2014	Common	3,821	\$0	0		D	

Explanation of Responses:

Matthew S. Gilman, Attorney

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} There is no conversion or exercise price for this stock unit.

^{2.} The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).